A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.
暂无分享,去创建一个
[1] J. Witte,et al. Genetic dissection of complex traits , 1996, Nature Genetics.
[2] J. Witte,et al. Genetic dissection of complex traits. , 1994, Nature genetics.
[3] T. Yee,et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease , 1995, The Lancet.
[4] P. Froguel,et al. Paraoxonase polymorphism in non-insulin dependent diabetes: A link between lipid oxidation and coronary heart disease , 1995 .
[5] A. Marian,et al. Apolipoprotein ε4 is not a genetic risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty , 1995 .
[6] P. Froguel,et al. The relationship between paraoxonase polymorphism and plasma lipids/lipoproteins in non-insulin dependent diabetes , 1995 .
[7] A. Marian,et al. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[8] A. Hamsten,et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[9] T. Iwamoto,et al. Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. , 1995, Circulation.
[10] 石上友章. Molecular Variant of Angiotensiongen Gene Is Associated With Coronary Atherosclerosis(冠状動脈硬化症とのアンジオテンシンノーゲン遺伝子多型との関連研究) , 1995 .
[11] L. Berkman,et al. Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.
[12] R. Ward,et al. Apolipoprotein Polymorphisms Fail to Define Risk of Coronary Artery Disease: Results of a Prospective, Angiographically Controlled Study , 1994, Circulation.
[13] S. Kanemitsu,et al. Effects of LDL apheresis on restenosis after angioplasty. , 1994, Chemistry and physics of lipids.
[14] D. Adler,et al. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. , 1993, Chemico-biological interactions.
[15] C. Abbott,et al. Is paraoxonase related to atherosclerosis. , 1993, Chemico-biological interactions.
[16] S. Adkins,et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.
[17] D. Adler,et al. The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.
[18] Philippe Amouyel,et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.
[19] P. Durrington,et al. Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.
[20] A. Motulsky,et al. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.
[21] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[22] C. Walker,et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.
[23] B. La Du,et al. The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.
[24] D. Evans,et al. Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.